Skip to content
StockMarketAgent
Direct answer
argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities. Fair value range: low $654, high $2709, with mid-point at $1486.
Stock analysis

ARGX fair value $654–$2,709

By StockMarketAgent.AI team· supervised by
Analizzato: 2026-05-20Prossimo aggiornamento: 2026-08-20Methodology v2.4Data cut-off: Quality gate: passSources: all material sources passed deterministic freshness/provenance gatesReview: automatedArchetype: Hyper-growth
View archive
Prezzo
$797.77
▲ +688.71 (+86.33%)
Valore equo
$1486
$654–$2709
Valutazione
Acquisto forte
confidence 82/100
Potenziale rialzo
+86.3%
upside to fair value
Margine di Sicurezza
$1263.51
MoS level · 15%
Capitalizzazione
$49.9B
P/E fwd 21.8
Fallback in ingleseIT
Mostrando la fonte in inglese mentre traduciamo
Questo report non è ancora stato tradotto. Aggiorna tra qualche minuto una volta che la coda di traduzione avrà recuperato.

§1 Sintesi

  • Commercial-stage status with visible traction in gMG/CIDP provides a reliable valuation floor.
  • Robust pipeline diversity reduces binary outcome risk compared to single-asset biotechs.
  • Forward earnings captures the massive earnings reset expected as assets reach peak penetration.
Fair value
$1,486
Margin of safety
+46.3%
Confidence
82/100
Moat
6.5/10

Educational analysis only — not financial advice. Always do your own due diligence.

$797.77Price
Low $654.18
Mid $1,486.48
High $2,709.48

argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities.

  • IP-protected antibody platform
    IP-protected antibody platform
  • Pipeline-in-a-product strategy
    Pipeline-in-a-product strategy
  • Cycle upside
    High demand for specialized autoimmune therapeutic platforms.

§2 Scenario ribassista

In a sustained high-cost environment where CIDP expansion falters, valuation relies entirely on established gMG revenues.

Come questa tesi può fallire

FcRn Class Competition

· Medium

Next-generation competitors outcompete on pricing or efficacy, eroding market share.

FV impact
Severe

Secondary Indication Failures

· Low

Regulatory delays or clinical failures across 3+ secondary indications cap revenue.

FV impact
Moderate

Margin Compression

· Medium

Failure to cross 15% operating margins by FY2027 due to sustained high SG&A.

FV impact
Moderate
Segnali di allerta precoce da monitorare
MetricaAttualeSoglia di attivazione
Operating margins failing to cross 15% by FY2027.MonitorDeterioration versus the report thesis
Regulatory rejection in secondary indications.MonitorDeterioration versus the report thesis
Clinical failure across more than 3 secondary indications.MonitorDeterioration versus the report thesis
Loss of market share in gMG to competitors.MonitorDeterioration versus the report thesis
Sustained increase in SG&A without revenue growth.MonitorDeterioration versus the report thesis

§3 Storia finanziaria

Conto economico — ultimi sei periodi
VoceT−0T−1T−2T−3CAGR
Periodo2022-12-312023-12-312024-12-312025-12-31Trend
Ricavi$410.7M$1.23B$2.19B$4.15B+116.2%
Utile lordo$381.3M$1.11B$1.96B$3.70B+113.3%
Reddito operativo$-723.9M$-420.6M$-17.8M$1.05B—
Utile netto$-709.6M$-295.1M$833.0M$1.29B—
EPS (diluito)$-13.05$-5.16$12.78$19.57—
EBITDA$-622.8M$-192.3M$105.2M$1.31B—
R&S$663.4M$859.5M$983.4M$1.36B+27.2%
SG&A$469.9M$709.5M$1.05B$1.36B+42.5%

Punteggi di qualità

OCF / Utile netto
0.53×
>1 indica alta qualità degli utili
Soglia di qualità contabile
Fail
Soglia corretta per settore
ROIC
13.8%
Rendimento del capitale investito
Sezione 3

Numbers analysis

Flusso di cassa

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Allocazione del capitale

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Abbonati individuali — da §4 in poi11 sezioni in più

Leggi l'analisi completa — 11 sezioni in più.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Report completo per ogni ticker coperto
24 mesi di archivio rating
Briefing della watchlist + avvisi di variazione del rating
Esportazione PDF + DOCX in qualsiasi lingua
Inizia la prova gratuita
Annulla in qualsiasi momento.
CASH FLOW FAQ

ARGX cash flow questions

  1. Free cash flow for ARGX (ARGX) is computed as operating cash flow minus capital expenditure. We report both the absolute level and the FCF margin against revenue, with five years of trajectory.

FAQ

ARGX — frequently asked questions

  1. Based on our latest analysis, ARGX looks meaningfully undervalued. The current price is $798 versus a composite fair-value midpoint of $1486 (range $654–$2709), which implies roughly 86.3% upside to the midpoint.

Related coverage

Names readers of ARGX also follow

Same archetype: hyper-growth